- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/725 - Récepteurs de lymphocytes-T
Détention brevets de la classe C07K 14/725
Brevets de cette classe: 8771
Historique des publications depuis 10 ans
|
405
|
511
|
718
|
832
|
1019
|
1192
|
989
|
883
|
792
|
399
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Immatics Biotechnologies GmbH | 1127 |
550 |
| The Trustees of the University of Pennsylvania | 4415 |
251 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3001 |
229 |
| The Regents of the University of California | 20745 |
155 |
| Memorial Sloan-Kettering Cancer Center | 2043 |
149 |
| Autolus Limited | 267 |
128 |
| Board of Regents, The University of Texas System | 6107 |
119 |
| Novartis AG | 10262 |
111 |
| Regeneron Pharmaceuticals, Inc. | 4701 |
108 |
| Juno Therapeutics, Inc. | 519 |
104 |
| Cellectis | 415 |
92 |
| Immunocore Limited | 235 |
91 |
| Kite Pharma, Inc. | 452 |
89 |
| City of Hope | 1030 |
87 |
| Lentigen Technology, Inc. | 107 |
80 |
| CRISPR Therapeutics AG | 367 |
78 |
| Fred Hutchinson Cancer Center | 475 |
74 |
| The Board of Trustees of the Leland Stanford Junior University | 6653 |
66 |
| Adaptimmune Limited | 158 |
66 |
| The General Hospital Corporation | 4870 |
57 |
| Autres propriétaires | 6087 |